文献速递白血病

2020年中国慢性髓性白血病患者酪氨酸激酶抑制剂治疗现状调查

[Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

2020年4-5月全国31省市2933例CML患者横断面问卷显示,84.6%首选伊马替尼、61.5%用原研药;40.4%曾转换TKI,初发慢性期患者72.9%获≥MMR。社会人口学与疾病分期影响TKI选择、转换和疗效。

要点

  • 2020年中国CML患者84.6%首选伊马替尼,61.5%使用原研药。
  • 40.4%曾转换TKI,初发慢性期中位治疗45个月72.9%获≥MMR。
  • 城镇户籍、高学历者更少首选仿制TKI,进展期更多首选二代TKI。

核心结论

  • 截至2020年,中国CML患者大多数首选并持续服用伊马替尼,半数以上服用原研药。
  • 社会人口学特征和疾病分期影响患者的TKI选择、药物转换和治疗反应。

研究设计与样本

  • 横断面问卷调查,2020年4月末至5月中旬在全国31个省市自治区开展。
  • 共纳入2933例CML受访者,男性1683例(57.4%),中位年龄38(16-87)岁。

主要发现

  • 一线选择伊马替尼2481例(84.6%),原研药1803例(61.5%);填表时用伊马替尼1765例(60.2%),原研药1791例(61.1%)。
  • 1185例(40.4%)曾经历TKI药物转换;1944例初发慢性期患者中位治疗45(3-227)个月,1417例(72.9%)获≥MMR。
  • 城镇户籍(OR=0.6,95%CI 0.5-0.8,P<0.001)、≥大学学历(OR=0.5,95%CI 0.4-0.7,P<0.001)、进展期(OR=0.5,95%CI 0.3-0.8,P=0.001)更少首选仿制TKI;中部地区比东部更多首选国产仿制TKI(OR=1.7,95%CI 1.4-2.0,P<0.001)。
  • 进展期更多首选二代TKI(OR=5.4,95%CI 3.6-8.2,P<0.001),≥60岁更少首选二代TKI(OR=0.4,95%CI 0.2-0.7,P=0.002)。
  • 诊断时进展期(OR=2.2,95%CI 1.6-3.2,P<0.001)、首选伊马替尼(OR=2.0,95%CI 1.6-2.6,P<0.001)、首选国产仿制药(OR=1.3,95%CI 1.1-1.6,P=0.002)、诊断距开始TKI时间更长(OR=1.2,95%CI 1.1-1.2,P<0.001)、服TKI时间更长(OR=1.1,95%CI 1.0-1.1,P<0.001)与转换比例增高相关;城镇户籍(OR=0.7,95%CI 0.6-0.8,P<0.001)、获≥MMR(OR=0.6,95%CI 0.5-0.8,P<0.001)、疗效未知(OR=0.7,95%CI 0.6-0.9,P=0.003)与转换比例低相关。

临床怎么用

  • 应关注城镇户籍、高学历及进展期患者更少选择仿制TKI的倾向,结合病情与经济因素个体化沟通TKI选择。
  • 对诊断距开始TKI时间较长、服TKI时间较长及首选伊马替尼或国产仿制药者,需警惕TKI转换风险并加强监测。
  • 对≥60岁患者需权衡二代TKI选择,对未获MMR者应评估转换史与年龄因素并优化后续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the current status of treatment choice and responses in patients with chronic myeloid leukemia (CML) in China. Methods: From the end of April to mid-May in 2020, a cross-sectional survey, by filling out a survey questionnaire, was conducted to explore the first-line choice of tyrosine kinase inhibitors (TKI) , current medications, drug switch and major molecular responses (MMR) as well as the variables associated with them in patients in China. Results: Data of 2933 respondents with CML from 31 provinces, municipalities, and autonomous regions across the country were included in this study. 1683 respondents (57.4%) were males. Median age was 38 (16-87) years old. 2481 respondents (84.6%) received imatinib as first-line TKI; 1803 (61.5%) , the original new drug (branded drug) . When completing the questionnaire, 1765 respondents (60.2%) were receiving imatinib; 1791 (61.1%) , branded drug. 1185 respondents (40.4%) had experienced TKI switch. With a median follow-up of 45 (3-227) months, 1417 of 1944 (72.9%) respondents with newly diagnosed CML in the chronic phase achieved MMR. Multivariate analysis showed that the respondents with urban household registration (OR=0.6, 95%CI 0.5-0.8, P<0.001) , ≥ bachelor degree (OR=0.5, 95%CI 0.4-0.7, P<0.001) , and in the advanced phase at diagnosis (OR=0.5, 95%CI 0.3-0.8, P=0.001) less preferred Chinese generic TKI, while the respondents from the central region in China more preferred Chinese generic TKI more than those from the eastern region (OR=1.7, 95%CI 1.4-2.0, P<0.001) . Moreover, the respondents in the advanced phase at diagnosis more preferred second-generation TKI (OR=5.4, 95%CI 3.6-8.2, P<0.001) ; those ≥60 years old, less preferred second-generation TKI (OR=0.4, 95%CI 0.2-0.7, P=0.002) . Being in the advanced phase at diagnosis (OR=2.2, 95%CI 1.6-3.2, P<0.001) , first-line choice of imatinib (OR=2.0, 95%CI 1.6-2.6, P<0.001) or Chinese generic drugs (OR=1.3, 95%CI 1.1-1.6, P=0.002) , longer interval from diagnose of CML to starting TKI treatment (OR=1.2, 95%CI 1.1-1.2, P<0.001) and longer duration of TKI therapy (OR=1.1, 95%CI 1.0-1.1, P<0.001) were significantly associated with TKI switch; urban household registration (OR=0.7, 95%CI 0.6-0.8, P<0.001) , ≥MMR (OR=0.6, 95%CI 0.5-0.8, P<0.001) and unknown response (OR=0.7, 95%CI 0.6-0.9, P=0.003) , no TKI switch. Female sex (OR=1.4, 95%CI 1.1-1.7, P=0.003) , urban household registration (OR=1.6, 95%CI 1.3-2.0, P<0.001) , front-line imatinib therapy (OR=1.4, 95%CI 1.1-1.9, P=0.016) and longer duration of TKI treatment (OR=1.2, 95%CI 1.2-1.3, P<0.001) were significantly associated with achieving a MMR or better response; age ≥ 60 years old (OR=0.7, 95%CI 0.4-1.0, P=0.047) and TKI switch (OR=0.6, 95%CI 0.5-0.7, P<0.001) , achieving no MMR. Conclusions: By 2020, the majority of Chinese CML patients received imatinib as the fist-line TKI therapy and continue to take it. More than half of TKIs were branded drugs. Socio-demographic characteristics and clinical variables affect their TKI choice, drug switch, and treatment response. 目的: 调查中国慢性髓性白血病(CML)患者的治疗现状。 方法: 横断面研究,2020年4月末至5月中旬,以填写调研问卷的形式在全国范围内调研CML患者,分析酪氨酸激酶抑制剂(TKI)一线选择、目前用药、药物转换和获得主要分子学反应(MMR)的比例及其影响因素。 结果: 2933份来自全国31个省市自治区CML受访者的问卷可供分析,男性1683例(57.4%),中位年龄38(16~87)岁。一线选择:伊马替尼2481例(84.6%),原创性新药(原研药)1803例(61.5%)。填写问卷时用药:伊马替尼1765例(60.2%),原研药1791例(61.1%)。共1185例(40.4%)受访者曾经历TKI药物转换。1944例初发慢性期受访者TKI中位治疗45(3~227)个月,1417例(72.9%)获得≥MMR的疗效。多因素分析显示,城镇户籍(OR=0.6,95%CI 0.5~0.8,P<0.001)、≥大学学历(OR=0.5,95%CI 0.4~0.7,P<0.001)和进展期(OR=0.5,95%CI 0.3~0.8,P=0.001)受访者更少首选仿制TKI,而来自中部地区受访者比东部地区更多首选国产仿制TKI(OR=1.7,95%CI 1.4~2.0,P<0.001)。进展期受访者更多首选二代TKI(OR=5.4,95%CI 3.6~8.2,P<0.001),≥60岁受访者更少首选二代TKI(OR=0.4,95%CI 0.2~0.7,P=0.002)。诊断时处于进展期(OR=2.2,95%CI 1.6~3.2,P<0.001)、首选伊马替尼(OR=2.0,95%CI 1.6~2.6,P<0.001)、首选国产仿制药(OR=1.3,95%CI 1.1~1.6,P=0.002)、诊断距开始TKI治疗的时间更长(OR=1.2,95%CI 1.1~1.2,P<0.001)和服用TKI的时间更长(OR=1.1,95%CI 1.0~1.1,P<0.001)与药物转换比例增高显著相关。城镇户籍(OR=0.7,95%CI 0.6~0.8,P<0.001)、获≥MMR(OR=0.6,95%CI 0.5~0.8,P<0.001)和疗效未知(OR=0.7,95%CI 0.6~0.9,P=0.003)与药物转换比例低显著相关。女性(OR=1.4,95%CI 1.1~1.7,P=0.003)、城镇户籍(OR=1.6,95%CI 1.3~2.0,P<0.001)、初始服用伊马替尼(OR=1.4,95%CI 1.1~1.9,P=0.016)和TKI治疗时间更长(OR=1.2,95%CI 1.2~1.3,P<0.001)与获得≥MMR显著相关,而年龄≥60岁(OR=0.7,95%CI 0.4~1.0,P=0.047)和药物转换(OR=0.6,95%CI 0.5~0.7,P<0.001)与未获得MMR显著相关。 结论: 截至2020年,中国CML患者中大多数首选并持续服用伊马替尼,半数以上服用原研药。社会人口学特征和疾病分期影响了患者的TKI选择、药物转换和治疗反应。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang HF, Zhang YL, Liu XL, et al. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34455739. doi:10.3760/cma.j.issn.0253-2727.2021.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。